Regarding the important role of PD-L1 expression by tumor cells, as described above, several studies have seen no or variable changes in PD-L1 expression in various cancer cell lines upon administration of MEKi, dependent on specific cell line, experimental context or duration of MEK inhibition (13, 183). This evidence concerns the gene CD274 and neoplasm.